Drugs / TOS-358
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05683418 | Feb 2023 → Dec 2027 expected | hormone receptor-positive breast cancer | Totus Medicines | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TOS-358 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05683418 ↗ |
| Action | Inhibit | “PIK3CA covalent inhibitor” NCT05683418 ↗ |
| Route | Oral | “TOS-358 administered orally on once a day (QD) and twice daily (BID) schedules” NCT05683418 ↗ |
| Target | PIK3CA | “PIK3CA covalent inhibitor” NCT05683418 ↗ |